News

Company News: ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeting 2019

Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation

ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.

The presentation titled “A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival” is scheduled for Sunday, March 31, 2019, as part of the session “Predictive Biomarkers for Immunotherapy” (12:45-2:45pm, Marcus Auditorium- Bldg A-GWCC).

The data will outline the effects of vaccination with ISA Pharmaceuticals´ therapeutic vaccine ISA101 during chemotherapy in 77 patients with advanced, recurrent or metastatic cervical cancer in a dose assessment study.

ISA101 is directed against the HPV16 oncoproteins E6/E7 and is the Company´s clinical-stage lead compound. It is being developed to treat HPV16-induced cancers such as cervical cancer and head-and-neck cancer. Clinical efficacy of ISA101 in combination with Regeneron’s PD-1 inhibitor cemiplimab is currently being tested in a randomized controlled Phase 2 trial in platinum refractory, HPV16-positive oropharyngeal cancer patients (NCT03669718). The results to be presented at AACR form the basis for a planned Phase 3 trial, in which the clinical benefit of the combination of ISA101 plus cemiplimab on top of standard-of-care chemotherapy will be studied in patients with advanced HPV16-positive cervical cancer.

###